Safety and Feasibility of Metformin for Sepsis Induced AKI
Key facts
- Who runs it
- Hernando Gomez
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 80 people enrolled
- Started
- 8 Nov 2023
- Ended
- 18 May 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Metformin low dose
- Metformin high dose
- Placebo
- Record updated
- 9 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age > 18 years
- Admitted to the ICU with sepsis per sepsis 3 criteria (defined as suspected infection or initiation of anti-biotics plus an increase in SOFA ≥ 2 points)
- Available enteral access
Who cannot take part
- Metformin use in the last 30 days from admission (assessed by medical or refill prescription history, and by medication reconciliation)
- History of allergy to metformin
- Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 prior to study drug administration
- Having severe metabolic acidosis defined by a venous or arterial pH < 7.2, with PaCO2 < 45 or PvCO2 < 50 mmHg at the time of enrolment; Patients co-enrolled in observational studies will be eligible for enrollment in LiMiT AKI. However, patients enrolled in interventional studies will need to be assessed on an individual basis to define whether the patient will be eligible; Children will be excluded from recruitment for this study. Etiologic causes of sepsis, acute kidney injury, and prognostic factors for children differ from those for adults; and for these reasons the proposed study focuses only on the adult population (age 18 years or older)
- Not expected to survive more than 24 hours
- Advanced directive to withhold life-sustaining treatment
- The treating clinician believes that participation in the trial would not be in the best interests of the patient
- Known or suspected pregnancy
- On mechanical circulatory support of any kind
Where in United States
- University of PittsburghPittsburgh, United States
About the trial
What the trial wants to find out
Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit. Sepsis is the most frequent cause of AKI, affecting 48 million people worldwide every year, and accounting for approximately 11 million of annual global deaths. Despite these figures, there are no known therapies to prevent or reverse septic AKI; hence this study aims to establish the safety and feasibility of the implementation of metformin in the treatment of AKI in patients with sepsis.
Read full original descriptionShow less
This study is the first critical step to inform the design of a future, full-scale efficacy randomized clinical trial.
The 3 groups in the trial
- Metformin 500 mgTreatment being tested
One 500mg tablet will be administered twice a day for the first (5) days of study treatment.
Treatment: Metformin low dose
- PlaceboPlacebo, for comparison
One inactive tablet will be administered twice a day for the first (5) days of study treatment.
- Metformin 1,000 mgTreatment being tested
One 1,000mg tablet will be administered twice a day for the first (5) days of study treatment.
Treatment: Metformin high dose
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Clinical Trial of the Safety and Feasibility of Metformin as a Treatment for Sepsis Induced AKI.
- Publications
- Record updated
- 9 June 2026